In an interview with PharmaShots, Christopher J. Calhoun, President & CEO at Paracrine shared his views on the transforming diabetes treatment with the first autologous, device-based cell therapy platform
Shots:
The company has developed the first autologous, device-based cell therapy platform which is ideally positioned to address conditions with underlying integers
Paracrine is a one-time, completely natural procedure that…
